|Mr. Gil Beyen BVBA||CEO & Director||591.35k||N/A||1962|
|Mr. Eric Soyer Ph.D.||CFO, COO & Deputy GM||363.83k||N/A||1966|
|Dr. JÃ©rÃ´me Bailly Pharm.D.||Deputy GM of Operations, Chief Quality Officer & Qualified Person||228.9k||N/A||1979|
|Dr. Stewart Craig||Chief Technical Officer||N/A||N/A||1962|
|Naomi Eichenbaum||Director Investor Relations||N/A||N/A||N/A|
|Mr. Brian Schwab||VP of Legal Affairs & Gen. Counsel||N/A||N/A||1965|
|Ms. Anne-CÃ©cile Fumey||HR Director||N/A||N/A||1975|
|Dr. Iman El-Hariry M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1960|
|Mr. Jean-Sebastien Cleiftie||Chief Bus. Officer||N/A||N/A||1973|
|Dr. Philip L. Lorenzi||Consultant & Member of Scientific Board||N/A||N/A||N/A|
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.